Sign in Sign up for free

Cellectis Revenue Y/Y

What is the Revenue Y/Y of Cellectis?

The Revenue Y/Y of Cellectis is -53.05%

What is the definition of Revenue Y/Y?

Yearly revenue growth is the percentage growth of the company’s revenue over trailing twelve months.

= (revenue past four quarters - revenue previous four quarters) / revenue previous four quarters

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Revenue Y/Y of companies in the Health Care sector on NASDAQ compared to Cellectis

What does Cellectis do?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Companies with revenue y/y similar to Cellectis